<DOC>
	<DOCNO>NCT02484768</DOCNO>
	<brief_summary>The purpose study establish proof-of-concept efficacy iron isomaltoside 1000 subject Restless Legs Syndrome . The study randomise , comparative , double-blind study 3 month extension . Subjects restless leg syndrome ( RLS ) randomise 2:1 one follow treat-ment group : - Group A ( 42 subject ) : 1000 mg iron isomaltoside 1000 - Group B ( 21 subject ) : Placebo infusion Furthermore , non-responders , continue meet entry requirement , receive 1000 mg iron isomaltoside 1000 week 6 .</brief_summary>
	<brief_title>IV Iron Treatment Restless Legs Syndrome</brief_title>
	<detailed_description>RLS disorder sensation prevalence around 2-5 % population . RLS extremely responsive dopaminergic agent , second issue iron deficiency state may precipitate RLS much 25-30 % subject iron deficiency . RLS appear related deficit brain iron content metabolism . Magnetic resonance imaging ( MRI ) image demonstrate decrease substantia nigra red nucleus iron content . The severity decrease brain iron content correlate severity symptom . A number patient quite resistant dietary iron repletion resolve symptom high dos intravenous ( IV ) iron . For individual subject , 4 phase study include teleconference ( TCs ) 2 visit . The treatment treatment evaluation main study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Diagnosis RLS base upon CHRLSq HTDI 3 . IRLS score ≥ 15 baseline evaluation RLS medication 4 . Willingness participate signing informed consent form 1 . Sferritin &gt; 300 ng/mL and/or TfS &gt; 50 % 2 . Iron overload disturbance utilisation iron ( e.g . haemochromatosis haemosiderosis ) 3 . Known hypersensitivity IV iron excipients investigational drug product 4 . Pregnant nursing woman . In order avoid pregnancy , woman childbearing potential use adequate contraception ( e.g . intrauterine device , hormonal contraceptive , double barrier method ) whole study period 7 day last dosing 5 . History active asthma within last 5 year 6 . Decompensated liver cirrhosis active hepatitis ( define ASAT ALAT &gt; 3 time upper limit normal ) 7 . Active acute chronic infection ( assessed clinical judgement supply WBC CRP ) 8 . Rheumatoid arthritis symptom sign active inflammation 9 . Pregnant nursing woman 10 . Previous IV iron treatment RLS 11 . IV iron treatment within 1 year prior screen 12 . Blood transfusion within 4 week prior screen 13 . Planned elective surgery study 14 . Participation interventional study study drug pass 5 halflives prior screen 15 . Any medical condition , opinion Investigator , may cause subject unsuitable completion study place subject potential risk study , e.g . history multiple allergy , malignancy , uncontrolled hypertension , unstable ischaemic heart disease , uncontrolled diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>